Johnson & Johnson Updates the Brand Identity of its MedTech Company Brands
Ethicon, DePuy Synthes, Biosense Webster, Abiomed and CERENOVUS will now go by Johnson & Johnson MedTech
The planned transition has no impact on the Company's products
September 10, 2024
Share
New Brunswick, NJ - (09/10/2024) - Today, Johnson & Johnson shared that its medical technology businesses - Ethicon, DePuy Synthes, Biosense Webster, Abiomed and CERENOVUS - will now go by the name Johnson & Johnson MedTech. This is the next step of Johnson & Johnson's updated brand and visual identity announced in September 2023.
This move underscores Johnson & Johnson's leadership in medical technology with a focus on cardiovascular, orthopaedic, surgery and vision solutions. Today's announcement has no impact on the medical technology products and solutions currently offered to customers.
Tim Schmid, Executive Vice President, Worldwide Chairman, MedTech, issued the following statement on this change:
"At Johnson & Johnson, we are addressing some of the largest unmet needs in healthcare through innovative medicine and medical technology. By bringing our medtech businesses together under the Johnson & Johnson name, the scale of our impact in healthcare will be even more apparent, unlocking new opportunities for us to strengthen our competitiveness.
"While Ethicon, DePuy Synthes, Biosense Webster, Abiomed, and CERENOVUS will now go by Johnson & Johnson MedTech, we will continue to honor the legacies of these brands by maintaining the products, services and approach to collaboration that made them some of the most trusted names in healthcare."
Partners, customers and consumers will begin to see the change come to life on social media channels and marketing materials over the coming weeks. The updated brand and visual identity will have no impact on the Johnson & Johnson MedTech portfolio.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more about our MedTech sector's global scale and deep expertise in cardiovascular, orthopaedics, surgery and vision solutions at https://thenext.jnjmedtech.com. Follow us at @JNJMedTech and on LinkedIn.